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S U M M A R Y
Objectives: Limited clinical experience exists regarding the management of prosthetic joint infection (PJI)
due to multidrug-resistant (MDR) Gram-negative organisms. We review three cases of carbapenem-
resistant Klebsiella pneumoniae (CRKP) complicating PJI.
Methods: This was a retrospective study of all patients at a tertiary care institution with CRKP
complicating PJI between January 2007 and December 2010. Demographic data, procedures, organisms
involved, length of stay, antibiotic treatments, and outcomes were collected. Antimicrobial susceptibility
testing was performed on CRKP isolates, and the mechanism of resistance was ascertained by PCR.
Results: This analysis demonstrated that: (1) the CRKP possessed blaKPC and were difﬁcult to eradicate
(persistent) in PJI; (2) multiple surgeries and antibiotic courses were undertaken and patients required a
prolonged length of stay; (3) resistance to colistin and amikacin emerged on therapy; (4) the same strain
of CRKP may be responsible for relapse of infection; (5) signiﬁcant morbidity and mortality resulted.
Conclusions: These cases highlight the opportunistic and chronic nature of CRKP in PJIs and the need for
aggressive medical and surgical treatment. Further investigations of the management of CRKP PJI and
new drug therapies for infections due to MDR Gram-negative organisms are urgently needed.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Primary total hip arthroplasty (THA) and total knee arthroplasty
(TKA) are among the most common operations in orthopedic
surgery, with nearly 800 000 THAs/TKAs performed annually in the§ This manuscript was presented at the 49th Annual Meeting of the Infectious
Diseases Society of America, Boston, Massachusetts, USA, October 20–23, 2011.
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).USA.1 Demand for THA and TKA is projected to signiﬁcantly
increase in the next two decades.2–4 One of the most devastating
complications of THA and TKA is infection of the prosthesis.
Patients with prosthetic joint infection (PJI) demonstrate a greater
morbidity, prolonged hospital stay, and incur additional costs of
care when compared to their non-infected counterparts.5 An
increase in the rates of THA and TKA revision, with infection
playing a role in up to 15% of cases, is occurring.6,7 While the
overall infection rates among primary arthroplasty are less than
2%, rates have increased signiﬁcantly for revision arthroplasty
surgery.7ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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(RA), underlying malignancy, use of corticosteroids, and increased
body mass index (BMI); the highest rates of infection occur in
patients with these risk factors undergoing THA.4 Staphylococcus
aureus and coagulase-negative staphylococci (CoNS) are the most
common causes of PJI. Currently, Gram-negative bacteria are
responsible for a substantial proportion of PJI, ranging from 5% to
23% of cases, especially among the elderly. Both Gram-negative
and Gram-positive bacteria have been associated with device-
related bioﬁlms, which protect the organisms from many
antimicrobial agents and the host immune system.8 However,
the clinical outcomes of PJI caused by Gram-negative bacteria are
reportedly less favorable than those of infection caused by Gram-
positive bacteria.9–11 The emergence of resistance to antibiotics
among Gram-negative bacteria that cause PJIs is also a major
concern. The emergence of resistance to ﬂuoroquinolones is linked
to failure of open debridement and loss of the prosthesis.12
In the past two decades, Klebsiella pneumoniae has emerged as a
multi- and extremely-drug resistant Gram-negative pathogen.13
Strains of K. pneumoniae have acquired plasmids with myriad
mechanisms of antibiotic resistance, such as qnr against ﬂuor-
oquinolones, 16S rRNA methylases against aminoglycosides, and,
against cephalosporins and carbapenems, extended-spectrum
beta-lactamases (ESBLs), New Delhi metallo-beta-lactamase
(NDM), and K. pneumoniae carbapenemase (KPC).14–17 Because
of the paucity of antibiotic options to treat them, infections caused
by carbapenem-resistant K. pneumoniae (CRKP) pose a signiﬁcant
threat to our health care system. Vulnerable patients in acute and
long-term care facilities experience bloodstream, respiratory, and
urinary tract infections that often lead to unwanted outcomes.18–20
CRKP-related PJIs may be particularly complicated by the
development of bioﬁlms. Although CRKP bioﬁlms have not been
documented in PJIs, they have been associated with endoscopes.21
Thus, the combination of plasmid-acquired and bioﬁlm-associated
microbial resistance may explain the severe outcomes described
here.
In this report, we recount our experience with three cases of
CRKP-related PJI. This single institution case series illustrates the
unique management challenges faced by clinicians and the adverse
clinical outcomes experienced by patients in an era of potentially
‘untreatable infections’.22Table 1
Characteristics and clinical outcomes of cases of prosthetic joint infection caused by ca
Variable Case 1 Case 2 
Age (years), sex 58, male 72, male
Comorbidities Osteoarthritis, diabetes Osteoar
artery d
heart fa
Onset of ﬁrst PJI (months from
index surgery)
60 36 
Primary organism PJI MSSA VSE,VRE
Onset of CRKP PJI (months from
ﬁrst PJI)
2 2 
Number of procedures (n) 10 12 
Antibiotics Oxacillin; piperacillin–tazobactam;
daptomycin and oral doxycycline;
tigecycline and ﬂuconazole; colistin,
amikacin, and tigecycline
Ciproﬂo
daptom
vancom
oxacillin
tigecycl
WBC  109/l (median (IQR)) 9.07 (0.63, 12.49) 8.45 (7.
Hospital LOS (days) 51 101 
Hospitalization costs ($) N/A N/A 
Functional status Above-the-knee amputation Full 
Outcomes Died Died 
RA, rheumatoid arthritis; PJI, prosthetic joint infection; MSSA, methicillin-susceptible Sta
resistant Enterococcus sp; CRKP, carbapenem-resistant Klebsiella pneumoniae; WBC, whi2. Materials and methods
We conducted a retrospective study of all patients at a tertiary
care institution (Cleveland Clinic Foundation, Cleveland, Ohio,
USA) with CRKP isolated from cultures of clinical samples between
January 2007 and December 2010. CRKP was deﬁned as K.
pneumoniae isolates having a minimum inhibitory concentration
(MIC) 2 mg/ml against ertapenem, meropenem, or imipenem and
a positive modiﬁed Hodge test (Clinical and Laboratory Standards
Institute (CLSI) 2009). CRKP-related PJI were diagnosed if CRKP was
recovered from intraoperative prosthetic joint and tissue speci-
mens, synovial ﬂuid culture, and/or from a sinus tract communi-
cating with the prosthesis. Demographic data, type and number of
procedures, involved organisms, hospitalization cost and length of
stay, antibiotic treatments, and outcomes were ascertained for
cases of CRKP-related PJI. Antimicrobial susceptibility testing was
performed on CRKP isolates, including the following antibiotics:
ciproﬂoxacin, amikacin, gentamicin, ceftazidime, piperacillin–
tazobactam, doxycycline, tigecycline, and colistin.
The mechanism of carbapenem resistance was ascertained by
PCR ampliﬁcation of blaKPC, blaNDM, blaVIM, and blaIMP.
14–17,19
Genetic similarity among CRKP strains was investigated by
repetitive sequence-based PCR (rep-PCR) using the DiversiLab
strain typing system (Bacterial BarCodes; bioMe´rieux) (as validat-
ed in Rice et al.14). Isolates with >95% similarity were considered of
the same clonal type.16 Multilocus sequence typing (MLST) was
performed on all CRKP strains as described by Diancourt et al.23
DNA sequences of seven housekeeping genes (rpoB, gapA, mdh, pgi,
phoE, infB, and tonB) were compared with the MLST database
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/).
3. Results
Between the years 2007 and 2010, 221 patients were identiﬁed
as having cultures of clinical samples with CRKP. Twenty-three
(10.4%) patients with CRKP possessed a bone and joint-related
infection. Three (1.3%) of these cases involved an infected
orthopedic joint prosthesis. All cases occurred in patients with
TKA, and in all cases CRKP were recovered as part of a
polymicrobial or ‘complex’ infection. The initial pathogen was
methicillin-susceptible S. aureus (MSSA) in two cases, whereas therbapenem-resistant Klebsiella pneumoniae
Case 3
 70, female
thritis, coronary
isease, congestive
ilure
RA on immunosuppression with
methotrexate and hydroxychloroquine
1
, Proteus mirabilis Corynebacterium sp and VSE
5
57
xacin, linezolid, and rifampin;
ycin and ciproﬂoxacin;
ycin and tigecycline ! doxycycline;
, oxacillin and
ine ! doxycycline
Vancomycin; tigecycline; colistin;
tigecycline; tigecycline; tigecycline
and vancomycin ! oral ciproﬂoxacin
and clindamycin; tigecycline; colistin;
tigecycline, and amikacin; ciproﬂoxacin
73, 9.75) 8.92 (7.40, 11.68)
225
850 000
Disarticulated
Alive with major disability
phylococcus aureus; VSE, vancomycin-susceptible Enterococcus sp; VRE, vancomycin-
te blood cell count; IQR, interquartile range; LOS, length of stay; N/A, not available.
Table 2
Antimicrobial susceptibility testing of carbapenem-resistant Klebsiella pneumoniae
isolates from prosthetic joint infections
Antibiotics Case 3, isolate 1
MIC (in mg/ml)
and interpretation
Case 3, isolate 6
MIC (in mg/ml)
and interpretation
Amikacin 4 S >64 R
Colistin <2 S >8 R
Gentamicin >16 R >16 R
Tigecycline 1 S 1 S
Tobramycin >16 R >16 R
Imipenem >16 R >16 R
MIC, minimum inhibitory concentration; S, susceptible; R, resistant.
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resistant enterococci (VRE), vancomycin-susceptible enterococci
(VSE), and Proteus mirabilis. Demographic data, comorbidities,
number of procedures, organisms involved, hospitalization cost
(on one patient only) and length of stay, antibiotic treatments, and
outcomes are summarized in Table 1.
A total of 10 CRKP isolates were saved from the three patients.
Results of antimicrobial susceptibility testing of CRKP isolates
from case 3 are presented in Table 2. Using validated PCR primers
and controls, all CRKP isolates were determined to harbor blaKPC.
Genetic typing with rep-PCR demonstrated a high percentage of
similarity between isolates belonging to two of the patients (cases
1 and 2). Case 3 was infected with CRKP with a different rep-PCR
pattern. However, the six CRKP isolates obtained from this patient
were similar to each other (Figure 1). MLST revealed that all
strains belonged to sequence type (ST) 258. Of note, ST258 and
the rep-PCR strain types identiﬁed in these three cases were
similar to the predominant CRKP strains in our institution (data
not shown).Figure 1. Dendrogram illustrating the results of molecular typing with rep-PCR of carba
infection. Isolates obtained from cases 1 and 2 share >97% similarity, indicating that the
strain type, but are similar to each other.4. Case studies
4.1. Case 1
A 58-year-old male suffering from osteoarthritis and diabetes
mellitus presented to the Cleveland Clinic with left knee pain and
swelling, fever, and hypotension. Clinical evaluation indicated that
the infection originated from an infected left TKA implanted 5
years earlier. Blood and synovial ﬂuid cultures obtained upon
admission grew methicillin-susceptible S. aureus (MSSA) (Table 1).
Antibiotic treatment with intravenous (IV) oxacillin was started
and a two-stage left knee revision arthroplasty was planned, with
initial explantation of the prosthesis and placement of an antibiotic
spacer. Two weeks after explantation and spacer placement, the
patient had a wound infection due to Alcaligenes faecalis. The
wound was debrided and antibiotics were changed to piperacillin–
tazobactam resulting in a good initial response.
Two months later, the patient presented with wound dehiscence
and cement exposure. Tissue cultures from the knee capsule grew
CRKP (see Figure 1, case 1, isolate 1) and VRE. After left medial and
lateral gastrocnemius muscle ﬂaps, split thickness skin grafting, and
exchange of the antibiotic spacer, he was started on IV daptomycin
and oral doxycycline. Within 2 months of this last procedure he
underwent another spacer exchange and radical knee debridement:
he required patellectomy and quadriceps plasty with rotation of the
muscle into the open wound area. Purulence was present in the
femoral and the tibial canals and in the posterior recesses of the
joint. Intraoperative cultures were positive for CRKP, Acinetobacter
baumannii, and Candida parapsilosis. He was discharged from the
hospital on IV tigecycline and oral ﬂuconazole only to be readmitted
a week later with wound drainage, fever, and hypotension. Synovial
ﬂuid and blood cultures were still positive for CRKP. Despite left
above-the-knee amputation, maximum medical support, and
combined antibiotic therapy with IV colistin, amikacin, and
tigecycline, the patient died on postoperative day 3.penem-resistant Klebsiella pneumoniae isolated from three cases of prosthetic joint
y belong to the same strain type. Isolates from case 3 belong to a different rep-PCR
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(26.7 mg/dl at the time of diagnosis, 24.6 mg/dl 24 h prior to
death); his white blood cell count (WBC) decreased abnormally
from 16.2  109/l to 1.9  109/l at the time of death.
4.2. Case 2
A 72-year-old male underwent left TKA for osteoarthritis,
complicated 3 years later by a late PJI with development of a
ﬁstulous tract. The patient was treated with a two-stage revision
with interval placement of an antibiotic spacer. Peri-articular soft
tissue cultures obtained intraoperatively were positive for Proteus
mirabilis, VRE, and VSE. Treatment with oral ciproﬂoxacin, line-
zolid, and rifampin were initiated. He was discharged to a skilled
nursing facility. Eight weeks after the placement of the antibiotic
spacer, he developed wound dehiscence and required re-revision
and spacer exchange; intraoperative cultures were sterile. He was
started on IV daptomycin and ciproﬂoxacin. Seven days later, the
patient developed bacteremia with methicillin-resistant S. aureus
(MRSA) and underwent evacuation of a hematoma and removal of
the tissue expander. At this time, intraoperative cultures grew
carbapenem-resistant A. baumannii and CRKP (see Figure 1, case 2,
isolate 1). He was treated with IV vancomycin and tigecycline for 3
months, followed by oral doxycycline for 2 months.
Twelve months after the second revision surgery, the patient
underwent re-implantation of the knee prosthesis. Intraoperative
cultures were positive for MSSA, and he was treated with IV
oxacillin. Three weeks postoperatively, he developed purulent
wound drainage and wound cultures grew carbapenem-resistant
A. baumannii, while synovial ﬂuid from the knee grew CRKP (see
Figure 1, case 2, isolate 2). He underwent synovectomy and
polyethylene removal, and all prosthetic joint components were
exchanged. After a second washout 1 week later, cultures
remained positive for CRKP (see Figure 1, case 2, isolate 3). He
completed an 8-week course of IV oxacillin and tigecycline and
was placed on a long-term suppressive regimen with oral
doxycycline. Unfortunately, the patient died 4 months later.
His CRP levels decreased from 2.4 mg/dl at the time of diagnosis
to 0.4 at time of discharge. Likewise, his WBC decreased from
12.5  109/l to 8.2  109/l at the time of discharge.
4.3. Case 3
A 70-year-old female underwent right knee arthroplasty
revision 1 month after a primary TKA, because of recurrent
dislocation of the prosthesis. She had a history of rheumatoid
arthritis treated with methotrexate and hydroxychloroquine. An
area of purulence within the subcutaneous tissue was noted
during the surgical revision, although it did not track to the
prosthesis. All hardware was removed, and an antibiotic-impreg-
nated cement was placed. Intraoperative tissue cultures were
positive for Corynebacterium sp and VSE. She received IV
vancomycin for 6 weeks followed by TKA re-implantation. The
postoperative period was complicated by multiple episodes of
infection at the surgical site, which required wound debridement
and wound therapy with negative-pressure. She was discharged to
a skilled nursing facility.
Five months after the primary TKA, CRKP (see Figure 1, case 3,
isolate 1) was isolated from the surgical wound and she underwent
hardware explantation. Peri-articular tissue cultures also grew
CRKP (see Figure 1, case 3, isolate 2). Initially, she was treated with
IV tigecycline, but it was stopped due to nausea. Therapy with IV
colistin was initiated, but was later discontinued due to circumoral
paresthesias. The patient was again treated with IV tigecycline, but
she developed drug-induced cholestasis and acute kidney injury.
Therefore, antibiotics were held.Two years after the primary TKA, she underwent a spacer
exchange; intraoperative cultures remained positive for CRKP (see
Figure 1, case 3, isolate 3), which was now resistant to amikacin.
Despite treatment with IV tigecycline (which was tolerated well), a
new lateral sinus tract developed requiring excision and spacer
exchange. Tissue cultures, however, were negative.
Six months after the spacer was exchanged, a second revision
was needed because the spacer fractured. She underwent a muscle
ﬂap from the left thigh to the right knee, which was complicated by
wound failure requiring debridement and an infection in the wound
from the donor area caused by Streptococcus pneumoniae and MRSA.
She completed a course of IV tigecycline and vancomycin, followed
by long-term oral ciproﬂoxacin and clindamycin.
Six months later, the spacer was removed and a distal femoral
TKA was placed. Cultures were negative, although she had been
empirically re-started on IV tigecycline before the surgery. On
postoperative day 7, she developed partial dehiscence of the
surgical wound and cultures grew CRKP, while cultures of the
synovial ﬂuid remained negative. Despite aggressive surgical
debridement, the patient became septic requiring amputation
above the right knee, followed by right hip disarticulation. Therapy
with IV colistin was initiated, but changed to IV tigecycline and
amikacin after development of acute kidney injury. Additionally,
she required ﬁve subsequent wound debridements. Culture of
tissue obtained from these procedures grew CRKP, eventually
resistant to amikacin and colistin. Amikacin was replaced with
ciproﬂoxacin, but CRKP (see Figure 1, case 3, isolate 6) persisted. As
there were no signs of systemic infection, all antibiotics were
discontinued. At 8-month follow-up, her surgical site appeared
well-healed with no signs of infection.
Her CRP levels decreased signiﬁcantly from 27.1 mg/dl at the
time of diagnosis to 0.6 mg/dl 24 h prior to discharge; her WBC
improved from 27.4  109/l to 8.1  109/l at the time of discharge.
5. Discussion
This unique case series serves to highlight the opportunistic,
deleterious, and chronic nature of CRKP as a cause of PJI. In our
series, CRKP PJIs exacted a tremendous cost in terms of morbidity,
disability, health care expenses, and lost lives. Poor clinical
outcomes occurred with CRKP PJI despite the implementation of
intensive medical and surgical treatment regimens. Patients with
multiple comorbidities may be mostly affected, and the MDR
proﬁle of the causative organisms may dramatically impact
effective antibiotic therapy. A notable aspect of these cases was
the persistence of CRKP, which also inﬂuenced length of stay and
the need for recovery in post-acute care facilities. The sums of
these factors lead us to conclude that CRKP PJIs are potentially
incurable infections. In addition we found that: (1) CRKP was very
difﬁcult to eradicate (persistent) in PJI; (2) multiple surgeries and
antibiotic courses need to be undertaken and patients require a
prolonged length of stay; (3) resistance to ‘last line agents’ (colistin
and amikacin) emerges on therapy; (4) the same strain of CRKP
may be responsible for relapse of infection.
When compared to 19 previously reported Gram-negative PJIs
with non-resistant strains,24 it is clear that CRKP-related infections
are more severe. Speciﬁcally, the median duration of hospital stay
was longer (101 days vs. 31 days), median WBC was higher
(14.92  109/l vs. 8.1  109/l), and mortality was higher (67% vs.
5%) for patients with CRKP PJIs. Another case series of 31 patients
with Gram-negative PJIs, reported that irrigation and debridement
alone was successful in eradicating 70% of infections.9 This was in
stark contrast to our CRKP patients, who underwent 10 or more
procedures. Interestingly, all of the previously reported Gram-
negative PJIs were monomicrobial, while CRKP arose at least 2
months after prosthetic infection with a different primary
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help prevent CRKP adverse outcomes.
The steady increase in the rates of CRKP infections in the USA is
worrisome. In 2007, up to 8% of all K. pneumoniae isolates reported
to the US Centers for Disease Control and Prevention (CDC) were
carbapenem-resistant (compared to less than 1% in 2000) due to
the widespread dissemination of the K. pneumoniae carbapene-
mase (KPC) gene, blaKPC.
25 Isolates of blaKPC- harboring CRKP
responsible for PJI in this report belonged to ST258, the
predominant lineage of KPC-harboring organisms in the USA
and in other parts of the world.26,27 The factors underlying the
success of this particular lineage or clonal group remain unclear,
although its MDR proﬁle likely confers a selective advantage in the
setting of broad-spectrum antibiotic therapy.
These cases of PJI illustrate the potential for ST258 KPC-
producing CRKP to cause persistent infection, as documented with
the use of molecular typing techniques (Figure 1). The long
duration of CRKP infection and colonization may create additional
opportunities for its dissemination in the health care system. This
may be of particular importance in long-term care facilities, which
have emerged as ‘silent reservoirs’ of MDR organisms, and where it
is more difﬁcult to implement antimicrobial stewardship and
infection control programs aimed at controlling CRKP.28
The successful management of PJIs depends on the combination
of surgical and antibiotic therapy, through different approaches,
including one-stage irrigation and debridement (with possible
polyethylene exchange), two-stage revision procedure, and a
hybrid modality with partial component exchange and retention of
the prosthesis.29,30 The risk of failure of these different approaches
is considerable and depends on the type of surgery performed. A
case series of 53 ﬁrst-time PJI, secondary to Gram-negative
organisms, reported a 2-year survival rate of 27% (95% conﬁdence
interval (CI) 16–34%) for debridement and retention of the
prosthesis, 69% (95% CI 59%-84%) for resection arthroplasty, and
87% (95% CI 80–99%) for two-stage exchange.10 Ineffective
antibiotic therapy may affect these outcomes, as demonstrated
by treatment failures when prostheses are retained and organisms
become resistant to ﬂuoroquinolones.12 Of note, CRKP are often
resistant to ﬂuoroquinolones (as well as beta-lactams), leaving
aminoglycosides, tigecycline, and polymyxins (chieﬂy in the form
of colistin) as the only active antibiotics against this type of
organism. Use of these agents may be limited by side effects and
toxicity (gastrointestinal in the case of tigecycline, renal with
aminoglycosides and polymyxins).31 Unfortunately, the doses of
polymyxins that are commonly used to treat CRKP may lead to a
relatively high rate of nephrotoxicity.32 Our series demonstrated
that resistance to amikacin and colistin can also occur during the
course of therapy. We note that in the case of amikacin resistance,
we suspect that either horizontal gene transfer has occurred
(acquisition of an aminoglycoside modifying enzyme on a mobile
plasmid) or there has been up-regulation of an efﬂux pump. The
mechanism of colistin resistance in K. pneumoniae is not fully
known, but likely does not involve a plasmid-mediated process.
In device-associated infections, it is possible that bacteria are
enclosed in slime-forming bioﬁlms.33 This complicates both
treatment strategies to eradicate bioﬁlms and diagnostics, as
bacteria tend to conglomerate, lowering the culture yield.
Sonication of the prosthesis could aid in higher culture results.34
Whether CRKP bioﬁlm formation plays a role in the resilient nature
of these infections is unknown.
Further complicating the treatment options for CRKP-related
PJI, pharmacologic studies suggest that the synovial ﬂuid and bone
distribution of the remaining active antibiotics against CRKP is
limited. Aminoglycosides appear to be less active in synovial ﬂuid
and bone, perhaps because of the acidic environment of the
synovial ﬂuid.35 Reports also indicate that colistin distribution tobone is only between 15% and 25%.36 However, when used in
combination with rifampin and imipenem,37 or with tigecycline,38
colistin has been reported to successfully treat MDR Pseudomonas
aeruginosa-related osteomyelitis.
Evidence exists suggesting that the outcomes of serious
infections (e.g., bacteremias) caused by KPC-producing CRKP are
improved with the use of combination therapy, either carbape-
nems in conjunction with tigecycline or with colistin,39 or
tigecycline combined with colistin.40 Interestingly, tigecycline
alone also seems to have poor distribution into the synovial ﬂuid
and bone. As shown in a report by Ji et al., the synovial and/or bone
concentrations of tigecycline ranged from 31% to 41% of those
found in the serum,41 which is typically below the MIC of most
Gram-negative bacteria. One of the few antibiotics with consistent
evidence of high bone penetration is fosfomycin (not available for
intravenous use in the USA). Although the bone concentrations of
fosfomycin may reach up to 43% of the serum concentration, these
concentrations are above the MIC of most bacteria.42 Fosfomycin
retains excellent activity against contemporary KPC-producing
CRKP isolates, and synergistic bactericidal activity against CRKP
has been demonstrated between fosfomycin and carbape-
nems.43,44 Therefore, fosfomycin, administered as part of combi-
nation therapy, has the potential to become a preferred antibiotic
for CRKP bone-related infections. However, the use of fosfomycin
in CRKP PJI has yet to be validated by clinical experience.
In conclusion, the devastating effects of CRKP PJI and their
almost intractable nature underscore the crisis precipitated by the
emergence of multidrug-resistant Gram-negative organisms. That
such infections can complicate TKA, an increasingly common
procedure aimed at improving function in older adults with
disability, should serve as a warning to health care professionals
and the public. Efforts to prevent and control CRKP applied
throughout the continuum of health care are justiﬁed to avoid this
type of infection. The future availability of new drugs containing
beta-lactamase inhibitors such as avibactam (formerly designated
as NXL-104) may offer a reprieve against KPC-producing organ-
isms, but would not overcome other carbapenemase types now
circulating worldwide (e.g., NDM, VIM, or IMP metallo-beta-
lactamases).45,46 In the meantime, the combined use of currently
available antibiotics as part of the management of these uniquely
challenging infections needs to be investigated further.
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